RJR-2403: A nicotinic agonist with CNS selectivity II. In vivo characterization

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1422-1429

  Lippiello, P M ^a   Bencherif, M ^a   Gray, J A ^b   Peters, S ^b   Grigoryan, G ^b   Hodges, H ^b   Collins, A C ^c  

^a R J REYNOLDS TOBACCO COMPANY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBOTENIC ACID; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE TARTRATE; NICOTINIC AGENT; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; BREATHING; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; MALE; MAZE TEST; MEMORY; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; STARTLE REFLEX; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; AVOIDANCE LEARNING; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; HEART RATE; MALE; MICE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR;

EID: 0030439041     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. ACHESON, R. M., FERRIS, M. J. AND SINCLAIR, N. M.: Transformations involving the pyrrolidine ring of nicotine. J. Chem. Soc. 2: 579-585, 1980.
2. AKAIKE, A., TAMURA, U., YOKOTA, T., SHIMOHAMA, S. AND KIMURA, J.: Nicotine induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644: 181-187, 1994.
3. ALKONDON, M. AND ALBUQUERQUE, E. X.: Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. J. Pharmacol. Exp. Ther. 265: 1455-1473, 1993.
4. ARNERIC, S. P., SULLIVAN, J. P., BRIGGS, C. A., DONNELLY-ROBERTS, D., ANDERSON, D. J., RASZKIEWICZ, J. L., HUGHES, M. L., CADMAN, E. D., ADAMS, GARVEY, D. S., WASICAK, J. T. AND WILLIAMS, M.: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 270: 310-318, 1994.
5. ARNERIC, S. P., SULLIVAN, J. P. AND WILLIAMS, M.: Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics. In Psychopharmacology: The Fourth Generation of Progress, ed. by F. E. Bloom and D. J. Kupfer, pp. 1-16, Raven Press, New York, 1995.
6. BARON, J. A.: The epidemiology of cigarette smoking and Parkinson's disease. In International Symposium on Nicotine: The Effects of Nicotine on Biological Systems. II. Advances in Pharmacological Sciences, ed. by P. B. S. Clarke, M. Quik, F. Adlkofer and K. Thurau, pp. 313-319, Birkhauser Verlag, Basel, 1994.
7. BENCHERIF, M., LOVETTE, M. E., ARRINGTON, S., FOWLER, K., REEVES, L., CALDWELL, W. S. AND LIPPIELLO, P. M.: Metanicotine: A nicotinic agonist with CNS selectivity - in vitro characterization (Abstract). Soc. Neurosci. 21: 605, 1995a.
8. BENCHERIF, M., FOWLER, K., LUKAS, R. J. AND LIPPIELLO, P. M.: Mechanisms of up-regulation of neuronal nicotinic acetylcholine receptors in clonal cell lines and primary cultures of fetal rat brain. J. Pharmacol. Exp. Ther. 275: 987-994, 1995b.
9. BENCHERIF, M., LOVETTE, M. E., FOWLER, K. W., ARRINGTON, S., REEVES, L., CALDWELL, W. S. AND LIPPIELLO, P. M.: RJR-2403: A nicotinic agonist with CNS selectivity. I. In vitro characterization. J. Pharmacol. Exp. Ther. 279: 1413-1421, 1996.
10. 3H] nicotine binding sites in human brain. J. Neurochem. 50: 1243-1247, 1988.
11. BRUCATO, F. H., LEVIN, E. D., ROSE, J. E. AND SWARTZWELDER, S.: Intracerebroventricular nicotine and mecamylamine alter radial-arm maze performance in rats. Drug Dev. Res. 31: 18-23, 1994.
12. BUCCAFUSCO, J. J. AND JACKSON, W. J.: Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging 12: 233-238, 1991.
13. CALDERON-GONZALEZ, R.: Attention deficit disorders spectrum: Neurological and neuropsychological basis. Internat. Pediat., 8: 176-188, 1993.
14. DECKER, M. W., MAJCHRZAK, M. J. AND ANDERSON, D. J.: Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 572: 281-285, 1992.
15. DECKER, M. W., BRIONI, J. D., SULLIVAN, J. P., BUCKLEY, M. J., RADEK, R. J., RASZKIEWICZ, J. L., KANG, C. H., KIM, D. J. B., GIARDINA, W. J., WASICAK, J. T., GARVEY, D. S., WILLIAMS, M. AND ARNERIC, S. P.: (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities. II. In vivo characterization. J. Pharmacol. Exp. Ther. 270: 319-328, 1994.
16. FREEDMAN, R., LEONARD, S., ADLER, L., BICKFORD, P., BYERLEY, W., COON, H., MILLER, C., LUNTZ-LEYBMAN, V., MYLES-WORSLEY, M., NAGAMOTO, H., ROSE, G., STEVENS, K. AND WALDO, M.: Nicotine receptors and the pathophysiology of schizophrenia. In International Symposium on Nicotine: The Effects of Nicotine on Biological Systems. II. Advances in Pharmacological Sciences, ed. by P. B. S. Clarke, M. Quik, F. Adlkofer and K. Thurau, pp. 307-312, Birkhauser Verlag, Basel, 1994.
17. GRAVES, A. B., VAN DUIJN, C. M., CHANDRA, V., FRATIGLIONI, L., HEYMAN, A., JORM, A. F., KOKMEN, E., KONDO, K., MORTIMER, J. A., ROCCA, W. A., SHALAT, S. L., SOININEN, H. AND HOFMAN, A.: Alcohol and tobacco consumption as risk factors for Alzheimer's disease: A collaborative re-analysis of case-control studies. Int. J. Epidemiology 20: S48-S57, 1991.
18. HODGES, H., ALLEN, Y., SINDEN, J., LANTOS, P. L. AND GRAY, J. A.: Effects of cholinergic-rich neural grafts on radial maze performance of rats after excitotoxic lesions of the forebrain projection system. II. Cholinergic drugs as probes to investigate lesion-induced deficits and transplant-induced functional recovery. Neuroscience 45: 609-623, 1991.
19. HODGES, H., SINDEN, J., TURNER, J. J., NETTO, C. A., SOWINSKI, P. AND GRAY, J. A.: Nicotine as a tool to characterize the role of the forebrain cholinergic projection system in cognition. In The Biology of Nicotine: Current Research Issues, ed. by P. M. Lippiello, A. C. Collins, J. A. Gray and J. H. Robinson, pp. 55-70, Raven Press, New York, 1992.
20. JONES, G. M., SAHAKIAN, B. J., LEVY, R., WARBURTON, D. M. AND GRAY, J. A.: Effects of acute subcutaneous nicotine on attention, information processing, and short-term memory in Alzheimer's disease. Psychopharmacology 108: 485-494, 1992.
21. KELLAR, K. J., WHITEHOUSE, P. J., MARTINO-BARROWS, A. M., MARCUS, K. AND PRICE, D. L.: Muscarinic and nicotinic binding sites in Alzheimer's disease cerebral cortex. Brain Research 436: 62-68, 1987.
22. LEVIN, E. D., CHRISTOPHER, N. C., BRIGGS, S. AND ROSE, J. E.: Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Cog. Brain. Res. 1: 137-143, 1993.
23. LIPPIELLO, P. M. AND FERNANDES, K. G.: Identification of putative high-affinity nicotinic receptors on cultured cortical neurons. J. Pharmacol. Exp. Ther. 246: 409-416, 1988.
24. LIPPIELLO, P. M., CALDWELL, W. S., MARKS, M. J. AND COLLINS, A. C.: Development of nicotinic agonists for Alzheimer disease treatment. In Alzheimer's Disease, Therapeutic Strategies, ed. by E. Giacobini and R. Becker, pp. 186-190, Birkhauser Boston, Inc., 1994.
25. LIPPIELLO, P. M., GRAY, J. A., PETERS, S., GRIGORYAN, G., HODGES, H., SUMMERS, K., GIACOBINI, E. AND COLLINS, A. C.: Metanicotine: A nicotinic agonist with CNS selectivity - in vivo characterization (Abstract). Soc. Neurosci. 21: 605, 1995.
26. MARKS, M. J., BURCH, J. B. AND COLLINS, A. C.: Effects of chronic nicotine infusion on tolerance development and cholinergic receptors. J. Pharmacol. Exp. Ther. 226: 806-816, 1983.
27. MARKS, M. J., ROMM, E., BEALER, S. AND COLLINS, A. C.: A test battery for measuring nicotine effects in mice. Pharmacol. Biochem. Behav. 23: 325-330, 1985.
28. NEWHOUSE, P. A., SUNDERLAND, T., TARIOT, P. N., BLUMHARDT, C. L., WEINGARTNER, H., MELLOW, A. AND MURPHEY, D. L.: Intravenous nicotine in Alzheimer's disease. A pilot study. Psychopharmacology 95: 171-175, 1988.
29. NITTA, A., KATONO, Y., ITO, A., HASEGAWA, T. AND NABESHIMA, T.: Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system. Pharm. Biochem. Behav. 49: 807-812, 1994.
30. 3H-acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72: 275-285, 1986.
31. REAVILL, C., WALTHER, B., STOLERMAN, I. P. AND TESTA, B.: Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacol. 29: 619-624, 1990.
32. SANBERG, P. R., MCCONVILLE, B. J., FOGELSON, H. M., MANDERSCHEID, P. Z., PARKER, K. W., BLYTHE, M. M., KLYKYLO, W. M. AND NORMAN, A. B.: Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed. & Pharmacother. 43: 19-23, 1989.
33. SCHWARTZ, R. D. AND KELLAR, K. J.: Nicotinic cholinergic receptor binding sites in brain: In vivo regulation. Science (Wash. D.C.) 220: 214-216, 1983.
34. SILVER, A. A., SHYTLE, R. D., PHILIPP, M. K. AND SANBERG, P. R.: Transdermal nicotine in Tourette's syndrome. In International Symposium on Nicotine: The Effects of Nicotine on Biological Systems. H. Advances in Pharmacological Sciences, ed. by P. B. S. Clarke, M. Quik, F. Adlkofer, and K. Thurau, pp. 293-299, Birkhauser Verlag, Basel, 1994.
35. 3H] GABA uptake in nucleus basalis lesioned rats. Brain Research 624: 295-298, 1993.
36. SUMMERS, K. L., CUADRA, G., NARITOKU, D. AND GIACOBINI, E.: Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex. Drug Dev. Res. 31: 108-119, 1994.
37. SUMMERS, K. L., LIPPIELLO, P. M. AND GIACOBINI, E.: A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. Neurochem. Res. 21: 1181-1186, 1996.
38. TILSON, H. A., MCLAMB, R. L., SHAW, S., ROGERS, B. C., PEDIATIKAKIS, P. AND COOK, L.: Radial-arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agonists. Brain Res. 438: 83-94, 1988.
39. VAN DUIJN, C. M. AND HOFMAN, A.: Relation between nicotine intake and Alzheimer's disease. Brit. Med. J. 302: 1491-1494, 1991.
40. WIDZOWSKI, D. V., CREGAN, E. AND BIALOBOK, P.: Effects of nicotinic agonists and antagonists on spatial working memory in normal adult and aged rats. Drug Dev. Res. 31: 24-31, 1994.
41. WILLIAMS, M., SULLIVAN, J. P. AND ARNERIC, S. P.: Neuronal nicotinic acetylcholine receptors. Drug News & Perspectives 7: 205-223, 1994.
42. WILSON, A. L., LANGLEY, L. K., MONLEY, J., BAUER, T., ROTTUNDA, S., MCFALLS, E., KOVERA, C. AND MCCARTEN, J. R.: Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety. Pharmacol. Biochem. Behav. 51: 509-514, 1995.
43. WONNACOTT, S., DRASDO, A., SANDERSON, E. AND ROWELL, P.: Presynaptic nicotinic receptors and the modulation of transmitter release. In The Biology of Nicotine Dependence, ed. by G. Bock and J. Marsh, pp. 87-101, John Wiley & Sons, Chichester, 1990.